Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent Technologies, Inc. Appoints Mikael Dolsten as Board of Directors

09/23/2021 | 04:05pm EDT

Agilent Technologies, Inc. announced that Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to Agilent’s board of directors, effective Sept. 21, 2021. Dr. Dolsten brings 30 years of pharma experience to the Agilent board. During his career, he has led teams that have selected more than 150 candidate drugs entering human clinical studies for the treatment or prevention of human disease and has been involved in advancing more than 30 drugs and vaccines to approval. Most recently, he co-led Pfizer’s recent collaboration with BioNTech to develop COMIRNATY (COVID-19 vaccine, mRNA).


© S&P Capital IQ 2021
All news about AGILENT TECHNOLOGIES, INC.
10/27Agilent Commits to Net-Zero Greenhouse Gas Emissions by 2050
PU
10/26Agilent Announced as My Green Lab's First ‘Transformative Level' Sponsor and Firs..
PU
10/26Agilent Announced as My Green Lab's First 'Transformative Level' Sponsor and First Spon..
PR
10/26DNA Script SAS announced that it has received ?142 million in funding from a group of i..
CI
10/21AGILENT TECHNOLOGIES : PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnost..
PU
10/21AGILENT TECHNOLOGIES : Technology Networks Limited - Agilent Science Futures, The Impact o..
AQ
10/14VC DAILY : Sprinter Health Collects $33 Million to Join Home-Healthcare Race
DJ
10/13AGILENT TECHNOLOGIES : Eli Lilly Get FDA's OK for Assay to Identify Early Breast Cancer
MT
10/13AGILENT TECHNOLOGIES : Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 phar..
BU
10/13Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-..
CI
More news
Analyst Recommendations on AGILENT TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 6 317 M - -
Net income 2021 1 075 M - -
Net Debt 2021 1 485 M - -
P/E ratio 2021 44,5x
Yield 2021 0,49%
Capitalization 47 001 M 47 001 M -
EV / Sales 2021 7,68x
EV / Sales 2022 7,14x
Nbr of Employees 16 700
Free-Float 99,7%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | A | US00846U1016 | MarketScreener
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 155,26 $
Average target price 172,40 $
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Koh Boon Hwee Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGILENT TECHNOLOGIES, INC.31.03%47 001
THERMO FISHER SCIENTIFIC30.61%240 886
DANAHER CORPORATION38.17%218 117
INTUITIVE SURGICAL, INC.27.97%124 669
SIEMENS HEALTHINEERS AG40.73%76 769
EDWARDS LIFESCIENCES CORPORATION28.24%72 350